Maha Assi, MD
Infectious Disease · Wichita, KSNPI 1922071224
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (38.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by AbbVie at 46.5% of the total. Reporting peaked in 2019 at $3,745 and has fallen 84.5% since, to $580 in 2025. Among infectious disease clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $74.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Ferring Pharmaceuticals Inc.$2K
- Octapharma USA, Inc.$494
- Insmed, Inc.$381
- Amgen$218
- Melinta Therapeutics, LLC$142
- plus $1K from 18 others
Across 344 payments — averaging $1062.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ADMA Biomanufacturing LLC$320K
- Octapharma USA, Inc.$24K
- Mannkind Corporation$13K
- Ferring Pharmaceuticals AS$8K
What the payments were for
- Consulting fees$2,64630%
- Speaking & faculty fees$3,45039%
- Food & beverage$2,80932%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $4,145 |
| Ferring Pharmaceuticals Inc. | 3 | $2,421 |
| Octapharma USA, Inc. | 2 | $494 |
| Insmed, Inc. | 25 | $381 |
| Amgen | 2 | $218 |
| Melinta Therapeutics, LLC | 9 | $142 |
| Hospira, Inc. | 8 | $139 |
| Gilead | 7 | $135 |
| Novo Nordisk | 1 | $121 |
| Recor Medical Inc | 1 | $110 |
| ADMA Biomanufacturing LLC | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $84 |
| AstraZeneca | 4 | $74 |
| Grifols USA, LLC | 3 | $68 |
| Pfizer | 2 | $51 |
| Merck | 3 | $46 |
| Shionogi Inc | 2 | $40 |
| Astellas Pharma US Inc | 2 | $29 |
| Davol Inc. | 1 | $26 |
| Invivyd Inc | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Romark Laboratories, LC | 1 | $22 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $18 |
| Bio Products Laboratory USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEFLARO$3,574
- REBYOTA$2,390
- OCTAGAM IMMUNE GLOBULIN (HUMAN)$477
- Tavneos$218
- DALVANCE$200
- Ozempic$121
- PARADISE RENAL DENERVATION SYSTEM$110
How this compares
$8,913 in reported general payments places this provider in the 95th percentile of 56 infectious disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 35 | $8,474 |
| Cefepime Hcl | 41 | $7,918 |
| Methenamine Hippurate | 109 | $5,404 |
| Vancomycin Hcl | 32 | $4,912 |
| Meropenem | 44 | $3,651 |
| Cefdinir | 19 | $965 |
| CeftriaxoneCeftriaxone Sodium | 27 | $910 |
| Minocycline Hcl | 18 | $758 |
| Cephalexin | 50 | $747 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $646 |
| Ethambutol Hcl | 17 | $638 |
| Sodium Chloride0.9 % Sodium Chloride | 29 | $460 |
| Doxycycline Hyclate | 26 | $304 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $258 |
| Fluconazole | 14 | $175 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Wichita
- Thomas MooreWichita$37K
- Margaret HaganWichita$4K
- Garret SeilerWichita$2K
- Keck HartmanWichita$2K
- Jerry PeterieWichita$2K
- Shelley JonesWichita$2K
- Wissam El AtrouniKansas City$15K
- John FriedOverland Park$7K
- Marjorie WongskhaluangLeawood$5K
- Apoorv KalraOverland Park$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.